Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optical coherence tomography in multiple sclerosis.

Elliot Frohman1, Fiona Costello, Robert Zivadinov

  • 1Department of Neurology, University of Texas Southwestern Medical Center at Dallas, 75235, USA. elliot.frohman@utsouthwestern.edu

The Lancet. Neurology
|September 22, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optic nerve involvement in multiple sclerosis diagnosis - Authors' reply.

The Lancet. Neurology·2026
Same author

Clinical and Demographic Predictors of Optic Neuritis Subtype.

Neuro-ophthalmology (Aeolus Press)·2026
Same author

Artificial Intelligence-Based Prognostic Models for Postoperative Outcomes in Vitreoretinal Surgery: A Systematic Review and Meta-Analysis.

Ophthalmology. Retina·2026
Same author

Visual Field Testing: The Key to Localizing Afferent Visual Pathway Lesions.

Neurologic clinics·2026
Same author

Healthcare Provider Perspectives on the Assessment and Management of Cerebral Visual Impairment in Children.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same author

Artificial Intelligence and Ocular Imaging in the Evaluation of Neurologic Disorders: The New Era of Neuro-Oculomics?

Seminars in neurology·2026
Same journal

Resolution of expression of concern-Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.

The Lancet. Neurology·2026
Same journal

UCL Queen Square Institute of Neurology: 75 years of innovation.

The Lancet. Neurology·2026
Same journal

Correction to Lancet Neurol 2026; 25: 631.

The Lancet. Neurology·2026
Same journal

Epstein-Barr virus and multiple sclerosis: from associations to mechanisms to potential therapies.

The Lancet. Neurology·2026
Same journal

Correction to Lancet Neurol 2025; 24: 740-52.

The Lancet. Neurology·2026
Same journal

Correction to Lancet Neurol 2026; 25: 357-67.

The Lancet. Neurology·2026
See all related articles

Optical coherence tomography offers a new way to measure vision changes in multiple sclerosis (MS). This retinal imaging technique can track neurodegeneration and help develop treatments for MS disability.

Area of Science:

  • Neuroscience
  • Ophthalmology
  • Neurology

Background:

  • Current methods for assessing multiple sclerosis (MS) disability lack precise clinical and anatomical correlations.
  • Structural biomarkers like MRI struggle to differentiate demyelination from axonal injury in the central nervous system (CNS).
  • Axonal degeneration in MS is linked to irreversible disability, necessitating quantifiable measures of axon loss for neuroprotective strategy evaluation.

Purpose of the Study:

  • To review the utility of optical imaging of the retina as a biomarker for neurodegeneration in multiple sclerosis.
  • To explore how structural changes in the visual system impact function in MS patients.
  • To highlight the potential of quantifiable visual function measures coupled with ocular imaging.

Main Methods:

Related Experiment Videos

  • Review of existing literature on optical coherence tomography (OCT) and its application in multiple sclerosis.
  • Correlation of quantifiable visual function tests with OCT-derived structural measures.
  • Analysis of OCT's ability to detect and quantify retinal nerve fiber layer (RNFL) changes related to neurodegeneration.

    • Main Results:

    • Optical coherence tomography provides quantifiable measures of retinal structural changes in MS.
    • These structural changes correlate with visual function deficits in MS patients.
    • Retinal imaging shows promise as a sensitive biomarker for neurodegeneration in MS.

    Conclusions:

    • Optical coherence tomography is a valuable tool for monitoring neurodegeneration in multiple sclerosis.
    • Retinal imaging can serve as a reliable biomarker for assessing disease progression and treatment efficacy in MS.
    • This approach facilitates a better understanding of the relationship between structural damage and functional impairment in MS.